Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Non Small Cell Lung Cancer Clinical Trial

Official title:

A Prospective, Randomized, Multicenter Real-world Study of Jinfukang Oral Liquid Combined With Chemotherapy in Treatment for Patients With Driver Gene-negative Advanced Non-small Cell Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05098990
• Other study ID #: ICM-JFK-CR01
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: October 25, 2021
• Est. completion date: August 15, 2024

Study information

• Verified date: October 2021
• Source: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
• Contact: Chunxue Chen
• Phone: 0755-83360999
• Email: Chenchunxue3[@]999.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, multicenter real-world study, which aims to investigate the efficacy and safety of Jinfukang oral liquid combined with chemotherapy as first-line treatment regimen for patients with driver-negative advanced NSCLC. 328 patients with unresectable stage IIIB-IV NSCLC and Qi-Yin deficiency will be divided into experimental (n=164) and control groups (n=164) according to the stratified blocked randomization.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 328
• Est. completion date: August 15, 2024
• Est. primary completion date: June 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. 18-80 years of age;

2. Patients with stage ?B-IV NSCLC are diagnosed by histopathology and cytology;

3. Patients' tumor tissues are unresectable as assessed by the investigator;

4. Have measurable disease based on RECIST 1.1;

5. Driver gene (EGFR/ALK/ROS1) is negative;

6. Patients who are receiving first-line platinum-doublet chemotherapy with remaining no fewer than 4 therapeutic cycles;

7. Patients in chemotherapy who combined with other systemic therapy (including but not limited to immune checkpoint inhibitors and anti-vascular targeted drugs) are not suitable, but with radiotherapy can be permitted;

8. During chemotherapy cycles, patients who take prior treatment with anticancer Chinese medicine less than 4 weeks can be enrolled after stopping medication. If administration time is longer than 4 weeks, at least 4 weeks washout period should be performed;

9. Patients are diagnosed with Qi-yin deficiency by the Syndrome Differentiation of Traditional Chinese Medicine;

10. The expected survival time =3 months;

11. The subjects volunteer to sign the informed consent.

Exclusion Criteria:

1. Allergy or hypersensitivity to ingredients of the study treatment formulation;

2. Pregnant or lactating women;

3. Patients with multiple brain metastases, multiple bone metastases and liver metastases, which have great influence on survival times;

4. Patients are enrolling in other therapeutic trials;

5. The investigator does not consider the participant to be eligible for this study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non Small Cell Lung Cancer

Intervention

Drug:
• Jinfukang oral liquid
Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
• Platinum-based doublet chemotherapy
Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Circulating tumor DNA (ctDNA) level measurement	Blood sample will be collected for ctDNA testing.	Up to 18 months
Primary	Progression Free Survival (PFS)	Time from the start of treatment to first progression disease or death, whichever is earlier, according to RECIST 1.1 criteria.	Up to 18 months
Secondary	Overall Survival (OS)	Time from randomization to death from any cause, according to RECIST 1.1 criteria.	Up to 18 months
Secondary	Objective Response Rate (ORR)	ORR is defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), according to RECIST 1.1 criteria.	Up to 18 months
Secondary	Disease Control Rate (DCR)	Disease control rate is defined as the proportion of patients with complete response (CR) or partial response (PR) or subjects with stable disease (SD), according to RECIST 1.1 criteria.	Up to 18 months
Secondary	Quality of Life as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)	30 quality of life questions for the participant to answer. The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much), and the final 2 questions answers range from 1 (Very Poor) to 7 (Excellent).	Up to 18 months
Secondary	Quality of Life as Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13 (EORTC QLQ-LC13)	13 quality of life questions for the participant to answer. The answers range from 1 (Not at All) to 4 (Very Much).	Up to 18 months
Secondary	Incidence and Severity of Adverse Events (AE)	An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.	Up to 18 months
Secondary	Incidence and Severity of Serious Adverse Event (SAE)	SAE refers to events that require hospitalization, prolong hospitalization, disability, impact on work ability, life-threatening or death, and congenital malformations that occur during clinical trials.	Up to 18 months
Secondary	Incidence and severity of Adverse Drug Reactions (ADR),Serious Adverse Drug Reactions (SADR) or Suspected Unexpected Serious Adverse Drug Reactions (SUSAR)	ADR: All noxious and unintended responses to a medicinal product related to any dose. SUSAR: all suspected adverse.	Up to 18 months
Secondary	Change from baseline of peripheral immune cell counts	Surface expression of CD3, CD4 and CD8 is assessed as a marker of absolute T lymphocyte, T helper cell and cytotoxic T lymphocyte, respectively.	Up to 18 months